17th International Congress on Infectious Diseases / International Journal of Infectious Diseases 45S (2016) 1-477 candidate BM212 was reported to be active against Mtb with an MIC of 1.5 mg/mL.BM212 belongs to the MmpL3 class of inhibitors which stops the transport of mycolic acids.
Methods & Materials: The structural similarity between an MmpL3 inhibitor BM212 and a cannabinoid receptor modulator rimonabant prompted us to investigate the anti-tubercular activity of rimonabant and its analogues. Accordingly several compounds were synthesized and their activity was evaluated against Mtb.
Results: Further optimization, particularly through incorporation of silicon into the scaffold resulted in new compounds with significant improvement in anti-tubercular activity against Mycobacterium tuberculosis (H37Rv).
Repurposing of rimonabant Conclusion:
A sila analogue turned out to be the most potent antimycobacterial compound (MIC, 31 ng/mL) from this series with an excellent selectivity index. Optimization of the series to improve its ADME properties is currently in progress. Results: A total of 6 patients with orbital tuberculosis were identified during the study period. Four of six patients were females. The age ranges of the patients from 7 years to 29 years. Four patients were less than 15 years, two patients were within 15 to 30 years. All the patients were immunocompetent. Two patients presented with lacrimal gland mass with proptosis, one patient with chronic orbital cellulitis, one patient with orbital cellulitis and tuberculosis osteomyelitis, one with upper lid mass with choroidal granuloma and one patient with upper lid mass. Mantoux test was performed in 4/6 patients and positive in all the four patients. Chest X was performed in 5/6 patients and no abnormality was noted in all these patients.ESR was elevated in 3/ 5 patients. Histopathology diagnosis was available for 5 patients and 4/5 patients showed granulomatous inflammation with caseous necrosis , one with tuberculosis osteomyelitis. Direct smear was positive for acid fast bacilli and culture grew Mycobacterium tuberculosis on LJ medium in all the patients. All the patients were started on anti tuberculosis treatment.
Conclusion: Orbital tuberculosis should be considered as a differential diagnosis in immunocompetent patients with orbital swelling and abscess in TB endemic countries. In majority of patients orbital tuberculosis occurs without systemic involvement. Background: Despite the availability of highly efficacious treatment for decades, tuberculosis (TB) remains a major global health problem. The widespread transmission of resistant variants of Mycobacterium tuberculosis, which does not respond to any of the commercial drugs, threatens health security of both developed and developing world. The urgent need of new antimycobacterial agents and development pathways is becoming more and more apparent.
Methods & Materials: More than 200 new diverse structures, including more than 50 new synthetic chiral compounds derived from natural terpenoids (+)-camphor and (-)-fenchone were synthesized. The compounds were evaluated for their in vitro antimycobacterial activity by proportional method against reference strain Mycobacterium tuberculosis H37Rv and multidrug resistant Mycobacterium tuberculosis strain 43.
Results: The quantitative structure-activity relationship (QSAR) revealed several structural requirements: two hydrogen bond donors, two or three rings and no large branched substituents. We describe the design of a set of nine novel camphane-based derivatives following these requirements. Four of them showed activities in the nanomolar range, significantly higher than the activities in the initial set. Many structures showed promising antimycobacterial activity (MIC up to 0.27 M) -10 to 20 fold higher than activity of ethambutol in combination with insignificant cytotoxicity (IC 50 more than 354 M toward human embryonal kidney cell line).
